Kevin D. McBryde
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kevin D. McBryde has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
David B. Kershaw
2 shared publicationsPatrick D. Brophy
2 shared publicationsTimothy L. Kudelka
2 shared publicationsJennifer Wilcox
The George Washington University
1 shared publicationJohn J. Gardner
1 shared publicationKanwal K. Kher
The George Washington University
1 shared publication
Latest Publications
- 1 June 2006
- Published by Elsevier in The Journal of Pediatrics
- Vol. 148 (6) , 770-778
Renal replacement therapy in the treatment of confirmed or suspected inborn errors of metabolism
- 1 June 2006
- Published by Elsevier in The Journal of Pediatrics
- Vol. 148 (6) , 770-778
Renal replacement therapy in the treatment of confirmed or suspected inborn errors of metabolism
- 18 June 2005
- Published by Springer Nature in Pediatric Nephrology
- Vol. 20 (8) , 1182-1185
Hyperphosphatemia due to fosphenytoin in a pediatric ESRD patient
Fosphenytoin is indicated for the treatment of generalized convulsions and seizures occurring during neurosurgery. Metabolites of fosphenytoin include phenytoin, phosphate, and formaldehyde. The drug monograph recommends caution in administering fosphenytoin to patients in whom phosphate restriction is necessary. Additionally, fosphenytoin has altered pharmacokinetics in end-stage renal disease patients. We report a 17-year old African-American male with end-stage renal disease who developed acute hyperphosphatemia to 3.9 mmol/L (12.1 mg/dL) following the intravenous administration of 1000 mg of fosphenytoin for an idiopathic complex partial seizure. To our knowledge, this is the first report of acute hyperphosphatemia due to fosphenytoin administration. Due to this risk of hyperphosphatemia, we recommend that fosphenytoin should be used with caution in the end-stage renal disease population.
- 18 June 2005
- Published by Springer Nature in Pediatric Nephrology
- Vol. 20 (8) , 1182-1185
Hyperphosphatemia due to fosphenytoin in a pediatric ESRD patient
Fosphenytoin is indicated for the treatment of generalized convulsions and seizures occurring during neurosurgery. Metabolites of fosphenytoin include phenytoin, phosphate, and formaldehyde. The drug monograph recommends caution in administering fosphenytoin to patients in whom phosphate restriction is necessary. Additionally, fosphenytoin has altered pharmacokinetics in end-stage renal disease patients. We report a 17-year old African-American male with end-stage renal disease who developed acute hyperphosphatemia to 3.9 mmol/L (12.1 mg/dL) following the intravenous administration of 1000 mg of fosphenytoin for an idiopathic complex partial seizure. To our knowledge, this is the first report of acute hyperphosphatemia due to fosphenytoin administration. Due to this risk of hyperphosphatemia, we recommend that fosphenytoin should be used with caution in the end-stage renal disease population.
- 1 April 2004
- Published by Elsevier in The Journal of Pediatrics
- Vol. 144 (4) , 536-540
Clearance of amino acids by hemodialysis in argininosuccinate synthetase deficiency
- 1 April 2004
- Published by Elsevier in The Journal of Pediatrics
- Vol. 144 (4) , 536-540
Clearance of amino acids by hemodialysis in argininosuccinate synthetase deficiency